Cargando…
Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells
Vildagliptin is a potent, orally active inhibitor of dipeptidyl peptidase-4 (DPP-4) for the treatment of type 2 diabetes mellitus. It has been reported that vildagliptin can cause hepatic dysfunction in patients. However, the molecular-mechanism of vildagliptin-induced liver dysfunction has not been...
Autores principales: | Asakura, Mitsutoshi, Karaki, Fumika, Fujii, Hideaki, Atsuda, Koichiro, Itoh, Tomoo, Fujiwara, Ryoichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069476/ https://www.ncbi.nlm.nih.gov/pubmed/27759084 http://dx.doi.org/10.1038/srep35633 |
Ejemplares similares
-
Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells
por: Yanagita, Teruyoshi, et al.
Publicado: (2008) -
GEP100/Arf6 Is Required for Epidermal Growth Factor-Induced ERK/Rac1 Signaling and Cell Migration in Human Hepatoma HepG2 Cells
por: Hu, ZhenZhen, et al.
Publicado: (2012) -
Role of hesperetin in LDL-receptor expression in hepatoma HepG2 cells
por: Bawazeer, Nora A., et al.
Publicado: (2016) -
Induction of apoptosis by Xiakemycin A in human hepatoma HepG2 cells
por: Chen, Chuan, et al.
Publicado: (2020) -
Antiproliferative and apoptotic effects of β-elemene on human hepatoma HepG2 cells
por: Dai, Zhi-Jun, et al.
Publicado: (2013)